Targeted Fatty Acid Therapy Shows Promise in Reversing Age-Related Vision Loss

Scientists Identify Novel Treatment Approach Using Polyunsaturated Fatty Acids to Combat Declining Eyesight

Researchers at the University of California, Irvine have demonstrated that strategic fatty acid supplementation may reverse age-related vision deterioration by targeting the ELOVL2 gene, a recognized aging marker. The groundbreaking findings, published in Science Translational Medicine in 2025, suggest a potential therapeutic pathway for combating vision loss and age-related macular degeneration (AMD).

Vision decline stands among the most prevalent indicators of aging, yet emerging research indicates this process may be reversible. A collaborative team from UC Irvine, Poland's Academy of Sciences, and Germany's Health and Medical University investigated how restoring specific lipids in the retina could halt or reverse visual deterioration.

The ELOVL2 Gene: A Key to Understanding Vision Aging

The research builds upon earlier investigations into Elongation of Very Long Chain Fatty Acids Protein 2 (ELOVL2), widely recognized as a biological marker of the aging process. According to Dr. Dorota Skowronska-Krawczyk, an associate professor in the Department of Physiology and Biophysics and the Department of Ophthalmology and Visual Sciences, reduced ELOVL2 enzyme activity directly correlates with deteriorating vision. Previous studies demonstrated that elevating this enzyme's activity in aging mice increased omega-3 fatty acid docosahexaenoic acid (DHA) levels in ocular tissue and enhanced visual capability.

Understanding the Mechanism of Age-Related Vision Loss

As individuals age, shifts in lipid metabolism diminish concentrations of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) throughout the retina. These molecular compounds prove essential for preserving visual acuity. Depletion of these lipids precipitates vision impairment and elevates AMD risk. The ELOVL2 gene orchestrates the production of both VLC-PUFAs and DHA, positioning it as a central determinant in ocular aging.

Experimental Success: Vision Restoration Through Fatty Acid Injection

The investigation explored whether supplying the eye with appropriate fatty acids could circumvent ELOVL2 limitations. Researchers administered specific polyunsaturated fatty acids to aging mice and documented enhanced visual performance. Significantly, the team observed no equivalent improvement when administering DHA alone, contradicting prevailing assumptions about DHA's singular effectiveness. Dr. Skowronska-Krawczyk emphasized: "Our work confirms that DHA alone cannot accomplish the task, but we identified an alternative fatty acid demonstrating efficacy in restoring vision in aged specimens and reversing aging markers at the molecular level."

Genetic Discoveries Point Toward Personalized Prevention

The research team identified genetic variations within the ELOVL2 enzyme associated with accelerated AMD progression. These discoveries establish a genetic foundation linking the disease to its aging component, potentially enabling identification of individuals at elevated risk for significant vision loss. Such information could facilitate more precise therapeutic interventions and preventative measures.

Broader Implications Beyond Vision

Dr. Skowronska-Krawczyk maintains conviction that ELOVL2 ranks among the most significant aging genes warranting investigation for anti-aging therapeutic development. The implications extend beyond ocular health. Collaborative investigations with UC San Diego scientists revealed that ELOVL2 deficiency accelerates immune cell aging. Preliminary findings suggest lipid supplementation throughout the body could counteract age-related immune system deterioration and potentially influence blood cancer development.

"Our initial investigation addressed vision loss therapy," Dr. Skowronska-Krawczyk notes, "but our emerging understanding of immune aging suggests supplementation treatments could simultaneously strengthen immune function."